Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.53 |
| ▸ | PIK3CA | P42336 | 19/20 | 0.50 |
| ▸ | PIK3CB | P42338 | 11/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | PRKDC | P78527 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16368696 | 0.88 | ALDH1A1 (0.51) | NOTUMPIK3CA | |
| SCHEMBL16368693 | 0.82 | KDM4E (0.47) | NOTUM | |
| SCHEMBL15188514 | 0.79 | NOTUM (0.56) | NOTUMPIK3CAPIK3CBPIK3CDPIK3CG | |
| SCHEMBL15188503 | 0.79 | NOTUM (0.53) | NOTUMPIK3CAPIK3CBPIK3CDPIK3CG | |
| SCHEMBL15188504 | 0.75 | RAB9A (0.42) | — | |
| SCHEMBL15188517 | 0.75 | NPC1 (0.45) | — | |
| SCHEMBL989599 | 0.74 | NOTUM (0.67) | NOTUMPIK3CAPIK3CB | |
| SCHEMBL989483 | 0.74 | NOTUM (0.70) | NOTUMPIK3CAPIK3CBPIK3CDPIK3CG | |
| SCHEMBL991030 | 0.74 | NOTUM (0.56) | NOTUMPIK3CAPIK3CB | |
| SCHEMBL4235720 | 0.73 | NOTUM (0.55) | NOTUMPIK3CAPIK3CBPIK3CDPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073942-B2 | Antiviral compounds with a heterotricycle moiety | LUPIN LIMITED (IN) | 2015-07-07 | — | — | US | disclosed |
| US-9073942-B2 | Antiviral compounds with a heterotricycle moiety | LUPIN LIMITED (IN) | 2015-07-07 | — | — | US | disclosed |
| US-20150010504-A1 | Antiviral Compounds with a Heterotricycle Moiety | LUPIN LIMITED (IN) | 2015-01-08 | — | — | US | disclosed |
| US-20150010504-A1 | Antiviral Compounds with a Heterotricycle Moiety | LUPIN LIMITED (IN) | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150010504-A1 | Antiviral Compounds with a Heterotricycle Moiety | HCCS, UQCRB, HAVCR2 | NOTUM 3574/4885PIK3CA 3024/4885PIK3CB 2224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.